Amicus Therapeutics to Present at Upcoming Investor Conferences
Amicus Therapeutics (Nasdaq: FOLD) announced that its senior leadership team will present at two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) announced that its senior leadership team will present at two upcoming virtual investor conferences. The SVB Leerink 10th Annual Global Healthcare Conference is scheduled for February 25, 2021, at 12:00 p.m. E.T., followed by the Cowen 41st Annual Health Care Conference on March 3, 2021, at 12:20 p.m. E.T. Live audio webcasts of these presentations will be available on Amicus Therapeutics' corporate website.
The company focuses on developing innovative treatments for rare metabolic diseases.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was -2.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences:
- SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 12:00 p.m. E.T.
- Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 12:20 p.m. E.T.
A live audio webcast of each presentation can be accessed via the Investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
CONTACT:
Investors:
Andrew Faughnan
Sr. Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.